ALNY vs. COR: A Head-to-Head Stock Comparison

Updated on July 8, 2025

Here’s a clear look at ALNY and COR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

ALNY’s market capitalization stands at 43.28 billion USD, while COR’s is 57.42 billion USD, indicating their market valuations are broadly comparable.

COR carries a higher beta at 0.57, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.

Symbol	ALNY	COR
Company Name	Alnylam Pharmaceuticals, Inc.	Cencora, Inc.
Country	US	US
Sector	Healthcare	Healthcare
Industry	Biotechnology	Medical - Distribution
CEO	Yvonne L. Greenstreet	Robert P. Mauch PharmD
Price	331.91 USD	296.23 USD
Market Cap	43.28 billion USD	57.42 billion USD
Beta	0.21	0.57
Exchange	NASDAQ	NYSE
IPO Date	June 1, 2004	April 4, 1995
ADR	No	No

Historical Performance

This chart compares the performance of ALNY and COR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ALNY vs. COR: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ALNY

-509.33%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

COR

240.99%

Medical - Distribution Industry

Max: 12.20%
Q3: 12.03%
Median: -50.14%
Q1: -62.68%
Min: -132.73%

COR’s Return on Equity of 240.99% is exceptionally high, placing it well beyond the typical range for the Medical - Distribution industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

ALNY vs. COR: A comparison of their ROE against their respective Biotechnology and Medical - Distribution industry benchmarks.

Return on Invested Capital

ALNY

-2.79%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

COR

10.23%

Medical - Distribution Industry

Max: 26.59%
Q3: 11.51%
Median: 7.70%
Q1: -0.02%
Min: -5.86%

COR’s Return on Invested Capital of 10.23% is in line with the norm for the Medical - Distribution industry, reflecting a standard level of efficiency in generating profits from its capital base.

ALNY vs. COR: A comparison of their ROIC against their respective Biotechnology and Medical - Distribution industry benchmarks.

Net Profit Margin

ALNY

-11.49%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

COR

0.55%

Medical - Distribution Industry

Max: 3.21%
Q3: 2.07%
Median: 0.70%
Q1: -1.43%
Min: -6.29%

COR’s Net Profit Margin of 0.55% is aligned with the median group of its peers in the Medical - Distribution industry. This indicates its ability to convert revenue into profit is typical for the sector.

ALNY vs. COR: A comparison of their Net Profit Margin against their respective Biotechnology and Medical - Distribution industry benchmarks.

Operating Profit Margin

ALNY

-4.91%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

COR

0.83%

Medical - Distribution Industry

Max: 5.22%
Q3: 3.23%
Median: 1.07%
Q1: -0.39%
Min: -4.51%

COR’s Operating Profit Margin of 0.83% is around the midpoint for the Medical - Distribution industry, indicating that its efficiency in managing core business operations is typical for the sector.

ALNY vs. COR: A comparison of their Operating Margin against their respective Biotechnology and Medical - Distribution industry benchmarks.

Profitability at a Glance

Symbol	ALNY	COR
Return on Equity (TTM)	-509.33%	240.99%
Return on Assets (TTM)	-6.40%	2.38%
Return on Invested Capital (TTM)	-2.79%	10.23%
Net Profit Margin (TTM)	-11.49%	0.55%
Operating Profit Margin (TTM)	-4.91%	0.83%
Gross Profit Margin (TTM)	86.01%	3.29%

Financial Strength

Current Ratio

ALNY

3.04

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

COR

0.87

Medical - Distribution Industry

Max: 1.38
Q3: 1.26
Median: 1.13
Q1: 0.92
Min: 0.87

COR’s Current Ratio of 0.87 falls into the lower quartile for the Medical - Distribution industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ALNY vs. COR: A comparison of their Current Ratio against their respective Biotechnology and Medical - Distribution industry benchmarks.

Debt-to-Equity Ratio

ALNY

11.28

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

COR

7.76

Medical - Distribution Industry

Max: 0.97
Q3: 0.97
Median: 0.65
Q1: 0.04
Min: 0.03

With a Debt-to-Equity Ratio of 7.76, COR operates with exceptionally high leverage compared to the Medical - Distribution industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

ALNY vs. COR: A comparison of their D/E Ratio against their respective Biotechnology and Medical - Distribution industry benchmarks.

Interest Coverage Ratio

ALNY

-0.79

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

COR

9.41

Medical - Distribution Industry

Max: 25.45
Q3: 12.43
Median: 7.07
Q1: 1.82
Min: -1.21

COR’s Interest Coverage Ratio of 9.41 is positioned comfortably within the norm for the Medical - Distribution industry, indicating a standard and healthy capacity to cover its interest payments.

ALNY vs. COR: A comparison of their Interest Coverage against their respective Biotechnology and Medical - Distribution industry benchmarks.

Financial Strength at a Glance

Symbol	ALNY	COR
Current Ratio (TTM)	3.04	0.87
Quick Ratio (TTM)	2.98	0.52
Debt-to-Equity Ratio (TTM)	11.28	7.76
Debt-to-Asset Ratio (TTM)	0.31	0.11
Net Debt-to-EBITDA Ratio (TTM)	-1.85	1.60
Interest Coverage Ratio (TTM)	-0.79	9.41

Growth

The following charts compare key year-over-year (YoY) growth metrics for ALNY and COR. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ALNY vs. COR: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ALNY vs. COR: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ALNY vs. COR: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

COR

0.73%

Medical - Distribution Industry

Max: 1.21%
Q3: 0.56%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 0.73%, COR offers a more attractive income stream than most of its peers in the Medical - Distribution industry, signaling a strong commitment to shareholder returns.

ALNY vs. COR: A comparison of their Dividend Yield against their respective Biotechnology and Medical - Distribution industry benchmarks.

Dividend Payout Ratio

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

COR

25.13%

Medical - Distribution Industry

Max: 31.84%
Q3: 21.47%
Median: 5.24%
Q1: 0.00%
Min: 0.00%

COR’s Dividend Payout Ratio of 25.13% is in the upper quartile for the Medical - Distribution industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

ALNY vs. COR: A comparison of their Payout Ratio against their respective Biotechnology and Medical - Distribution industry benchmarks.

Dividend at a Glance

Symbol	ALNY	COR
Dividend Yield (TTM)	0.00%	0.73%
Dividend Payout Ratio (TTM)	0.00%	25.13%

Valuation

Price-to-Earnings Ratio

ALNY

-159.59

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

COR

33.90

Medical - Distribution Industry

Max: 34.27
Q3: 27.58
Median: 25.75
Q1: 22.28
Min: 18.73

A P/E Ratio of 33.90 places COR in the upper quartile for the Medical - Distribution industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

ALNY vs. COR: A comparison of their P/E Ratio against their respective Biotechnology and Medical - Distribution industry benchmarks.

Forward P/E to Growth Ratio

ALNY

-43.29

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

COR

3.36

Medical - Distribution Industry

Max: 3.40
Q3: 2.79
Median: 2.36
Q1: 2.08
Min: 1.94

A Forward PEG Ratio of 3.36 places COR in the upper quartile for the Medical - Distribution industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.

ALNY vs. COR: A comparison of their Forward PEG Ratio against their respective Biotechnology and Medical - Distribution industry benchmarks.

Price-to-Sales Ratio

ALNY

18.43

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

COR

0.19

Medical - Distribution Industry

Max: 1.08
Q3: 0.89
Median: 0.25
Q1: 0.18
Min: 0.06

COR’s P/S Ratio of 0.19 aligns with the market consensus for the Medical - Distribution industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ALNY vs. COR: A comparison of their P/S Ratio against their respective Biotechnology and Medical - Distribution industry benchmarks.

Price-to-Book Ratio

ALNY

372.86

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

COR

56.68

Medical - Distribution Industry

Max: 8.13
Q3: 8.13
Median: 2.74
Q1: 2.19
Min: 1.20

At 56.68, COR’s P/B Ratio is at an extreme premium to the Medical - Distribution industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

ALNY vs. COR: A comparison of their P/B Ratio against their respective Biotechnology and Medical - Distribution industry benchmarks.

Valuation at a Glance

Symbol	ALNY	COR
Price-to-Earnings Ratio (P/E, TTM)	-159.59	33.90
Forward PEG Ratio (TTM)	-43.29	3.36
Price-to-Sales Ratio (P/S, TTM)	18.43	0.19
Price-to-Book Ratio (P/B, TTM)	372.86	56.68
Price-to-Free Cash Flow Ratio (P/FCF, TTM)	-574.08	16.06
EV-to-EBITDA (TTM)	-285.32	17.22
EV-to-Sales (TTM)	18.55	0.20